Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 27, 2017 - Issue 6
Submit an article Journal homepage
453
Views
28
CrossRef citations to date
0
Altmetric
Review

mGlu5 negative allosteric modulators: a patent review (2013 - 2016)

Kyle A. EmmitteDepartment of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, USACorrespondence[email protected]
View further author information
Pages 691-706 | Received 11 Nov 2016, Accepted 06 Jan 2017, Published online: 19 Jan 2017

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Laura Musazzi. (2021) Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery. Expert Opinion on Drug Discovery 16:2, pages 147-157.
Read now

Articles from other publishers (27)

Giovanni Vitale, Gaetano Terrone, Samuel Vitale, Francesca Vitulli, Salvatore Aiello, Carmela Bravaccio, Simone Pisano, Ilaria Bove, Francesca Rizzo, Panduranga Seetahal-Maraj & Thomas Wiese. (2023) The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex. Biomedicines 11:12, pages 3241.
Crossref
Yonglei Du, Feng Gao, Hongwei Sun, Chenglin Wu, Guoqi Zhu & Manzhou Zhu. (2023) Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice. European Journal of Medicinal Chemistry 261, pages 115855.
Crossref
Simona D’Antoni, Sara Schiavi, Valeria Buzzelli, Samuele Giuffrida, Alessandro Feo, Fabrizio Ascone, Carla Letizia Busceti, Ferdinando Nicoletti, Viviana Trezza & Maria Vincenza Catania. (2023) Group I and group II metabotropic glutamate receptors are upregulated in the synapses of infant rats prenatally exposed to valproic acid. Psychopharmacology 240:12, pages 2617-2629.
Crossref
Abdullahi Ibrahim Uba, John Chea, Hannah Hoag, Mariya Hryb, Candice Bui-Linh & Chun Wu. (2022) Binding of a positive allosteric modulator CDPPB to metabotropic glutamate receptor type 5 (mGluR5) probed by all-atom molecular dynamics simulations. Life Sciences 309, pages 121014.
Crossref
Li Gu, Wen-Yuan Luo, Ning Xia, Jian-Nan Zhang, Jing-Kai Fan, Hui-Min Yang, Meng-Chen Wang & Hong Zhang. (2022) Upregulated mGluR5 induces ER stress and DNA damage by regulating the NMDA receptor subunit NR2B. The Journal of Biochemistry 171:3, pages 349-359.
Crossref
Khaled S. Abd-Elrahman & Stephen S.G. Ferguson. (2022) Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease. Annual Review of Pharmacology and Toxicology 62:1, pages 235-254.
Crossref
Lisa Barbaro, Alice L. Rodriguez, Ashlyn N. Blevins, Jonathan W. Dickerson, Natasha Billard, Olivier Boutaud, Jerri L. Rook, Colleen M. Niswender, P.Jeffrey ConnDarren W. Engers & Craig W. Lindsley. (2021) Discovery of “Molecular Switches” within a Series of mGlu 5 Allosteric Ligands Driven by a “Magic Methyl” Effect Affording Both PAMs and NAMs with In Vivo Activity, Derived from an M 1 PAM Chemotype . ACS Bio & Med Chem Au 1:1, pages 21-30.
Crossref
Ya-Nan Zhang, Jing-Kai Fan, Li Gu, Hui-Min Yang, Shu-Qin Zhan & Hong Zhang. (2021) Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson’s disease. Journal of Neuroinflammation 18:1.
Crossref
Ting-ting Fu, Gao Tu, Meng Ping, Guo-xun Zheng, Feng-yuan Yang, Jing-yi Yang, Yang Zhang, Xiao-jun Yao, Wei-wei Xue & Feng Zhu. (2020) Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors. Acta Pharmacologica Sinica 42:8, pages 1354-1367.
Crossref
Johannes Petzold, Karen K. Szumlinski & Edythe D. London. (2021) Targeting mGlu5 for Methamphetamine Use Disorder. Pharmacology & Therapeutics 224, pages 107831.
Crossref
Yuan Wang, Li Gu, Hui Min Yang & Hong Zhang. (2021) Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model. NeuroToxicology 84, pages 14-29.
Crossref
Jian-Nan Zhang, Yan-Lin Huang, Hui-Min Yang, Yuan Wang, Li Gu & Hong Zhang. (2021) Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease. Molecular and Cellular Neuroscience 110, pages 103572.
Crossref
Angela Arsova, Thor C. Møller, Line Vedel, Jakob Lerche Hansen, Simon R. Foster, Karen J. Gregory & Hans Bräuner-Osborne. (2020) Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5. Molecular Pharmacology 98:1, pages 49-60.
Crossref
Laura Pérez-Benito, Claudia Llinas del Torrent, Leonardo Pardo & Gary Tresadern. 2020. From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors. From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors 1 33 .
Junliang Hao & Qi Chen. (2019) Insights into the Structural Aspects of the mGlu Receptor Orthosteric Binding Site. Current Topics in Medicinal Chemistry 19:26, pages 2421-2446.
Crossref
Adrienne Müller Herde, Yoan Mihov, Stefanie D. Krämer, Linjing Mu, Antoine Adamantidis, Simon M. Ametamey & Gregor Hasler. (2019) Chronic Nicotine Exposure Alters Metabotropic Glutamate Receptor 5: Longitudinal PET Study and Behavioural Assessment in Rats. Neurotoxicity Research 36:4, pages 806-816.
Crossref
Wen Yuan Luo, Su Qian Xing, Ping Zhu, Chen Guang Zhang, Hui Min Yang, Nicholas Van Halm-Lutterodt, Li Gu & Hong Zhang. (2019) PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson’s Disease. Neurotherapeutics 16:3, pages 761-783.
Crossref
John A. Christopher, Zoltán Orgován, Miles CongreveAndrew S. DoréJames C. ErreyFiona H. MarshallJonathan S. MasonKrzysztof OkrasaPrakash RucktooaMaria J. Serrano-VegaGyörgy G. Ferenczy & György M. Keserű. (2018) Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu 5 ) X-ray Structures . Journal of Medicinal Chemistry 62:1, pages 207-222.
Crossref
Joanna M. Wierońska & Andrzej Pilc. (2019) Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. Pharmacology & Therapeutics 193, pages 75-82.
Crossref
Andrew S. Felts, Katrina A. Bollinger, Christopher J. Brassard, Alice L. Rodriguez, Ryan D. Morrison, J. Scott Daniels, Anna L. Blobaum, Colleen M. Niswender, Carrie K. Jones, P. Jeffrey Conn, Kyle A. Emmitte & Craig W. Lindsley. (2019) Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic & Medicinal Chemistry Letters 29:1, pages 47-50.
Crossref
Tingting Fu, Guoxun Zheng, Gao Tu, Fengyuan Yang, Yuzong Chen, Xiaojun Yao, Xiaofeng Li, Weiwei Xue & Feng Zhu. (2018) Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations. ACS Chemical Neuroscience 9:6, pages 1492-1502.
Crossref
Andrew S. Felts, Alice L. Rodriguez, Ryan D. Morrison, Anna L. Blobaum, Frank W. Byers, J. Scott Daniels, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley & Kyle A. Emmitte. (2018) Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic & Medicinal Chemistry Letters 28:10, pages 1679-1685.
Crossref
Andrew S. Felts, Alice L. Rodriguez, Ryan D. Morrison, Katrina A. Bollinger, Daryl F. Venable, Anna L. Blobaum, Frank W. Byers, Analisa Thompson Gray, J. Scott Daniels, Colleen M. Niswender, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley & Kyle A. Emmitte. (2017) Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic & Medicinal Chemistry Letters 27:21, pages 4858-4866.
Crossref
Antonia F. Stepan, Michelle M. Claffey, Matthew R. Reese, Gayatri Balan, Gabriela Barreiro, Jason Barricklow, Michael J. Bohanon, Brian P. Boscoe, Gregg D. Cappon, Lois K. Chenard, Julie Cianfrogna, Laigao Chen, Karen J. Coffman, Susan E. Drozda, Joshua R. Dunetz, Somraj Ghosh, Xinjun Hou, Christopher Houle, Kapil Karki, John T. Lazzaro, Jessica Y. Mancuso, John M. Marcek, Emily L. Miller, Mark A. Moen, Steven O’Neil, Isao Sakurada, Marc Skaddan, Vinod Parikh, Deborah L. Smith, Patrick Trapa, Jamison B. Tuttle, Patrick R. Verhoest, Daniel P. Walker, Annie Won, Ann S. Wright, Jessica Whritenour, Kenneth Zasadny, Margaret M. Zaleska, Lei Zhang & Christopher L. Shaffer. (2017) Discovery and Characterization of ( R )-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1- c ][1,4]oxazin-4(9 H )-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates . Journal of Medicinal Chemistry 60:18, pages 7764-7780.
Crossref
Thomas K. David, Nayak K. Prashanth, M. Rajendraswami, Devendrareddy Pallalu, Arlindo L. Castelhano, Michael J. Kates, Anna L. Blobaum, Carrie K. Jones, Kyle A. Emmitte, P. Jeffrey Conn & Craig W. Lindsley. (2017) Development and kilogram-scale synthesis of mGlu5 negative allosteric modulator VU0424238 (auglurant). Tetrahedron Letters 58:36, pages 3554-3558.
Crossref
Andrew S. Felts, Alice L. Rodriguez, Anna L. Blobaum, Ryan D. Morrison, Brittney S. Bates, Analisa Thompson Gray, Jerri M. Rook, Mohammed N. Tantawy, Frank W. Byers, Sichen Chang, Daryl F. Venable, Vincent B. Luscombe, Gilles D. Tamagnan, Colleen M. Niswender, J. Scott Daniels, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley & Kyle A. Emmitte. (2017) Discovery of N -(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation . Journal of Medicinal Chemistry 60:12, pages 5072-5085.
Crossref
János Galambos, Attila Bielik, Gábor Wágner, György Domány, János Kóti, Zoltán Béni, Áron Szigetvári, Zsuzsanna Sánta, Zoltán Orgován, Amrita Bobok, Béla Kiss, Mónika L. Mikó-Bakk, Mónika Vastag, Katalin Sághy, Mikhail Krasavin, Krisztina Gál, István Greiner, Zsolt Szombathelyi & György M. Keserű. (2017) Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu 5 ) receptor negative allosteric modulators. European Journal of Medicinal Chemistry 133, pages 240-254.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.